相关实验视频
Updated: Jun 29, 2025
07:44
A Porcine Model of Acute Autologous Pulmonary Embolism
Published on: September 6, 2024
358
在肺栓塞反应小组注册表中比较治疗方法和随后的结果
Anthony J Weekes1, Ariana Trautmann1, Parker L Hambright1
1Department of Emergency Medicine, Atrium Health's Carolinas Medical Center, Charlotte, North Carolina, USA.
Critical care research and practice
|April 1, 2024
概括
肺栓塞 (PE) 的严重程度会影响治疗和结果. 对严重PE的先进干预与死亡,病情恶化和严重出血的风险更高有关,但导管导向治疗可能会比系统性血栓溶解减少出血.
科学领域:
- 肺部医学 肺部医学
- 心脏病学 心脏病学
- 紧急医疗 紧急医疗
背景情况:
- 肺栓塞 (PE) 是致病率和死亡率的重要原因.
- 风险分层对于引导PE治疗策略至关重要.
- 了解PE严重程度,出血风险和治疗方法之间的相互作用对于优化患者护理至关重要.
研究的目的:
- 调查肺栓塞严重程度与出血风险之间的关联.
- 分析不同治疗方法 (抗凝固单疗与先进干预) 如何影响结果.
- 确定PE患者死亡,临床恶化和严重出血的预测因素.
主要方法:
- 对11家医院的成人急诊室 (ED) 患者登记处的二次分析.
- 患者根据PE严重程度 (高风险,中高,中低,低风险) 和出血风险进行分类.
- 结果包括治疗方法,死亡,临床恶化和严重出血.
主要成果:
- 先进的干预措施在高风险和中高风险PE患者中更为常见.
- 严重出血与高级干预 (OR: 5.2 立即, 3.3 延迟) 和高风险PE严重程度 (OR: 3.4) 有显著关联.
- 高风险PE是高级干预使用 (OR:5.3) 和临床恶化 (OR:56.3) 的强有力的预测因素.
结论:
- 在PE中使用高级干预与更高度的患者和死亡,临床恶化和严重出血的风险增加有关.
- 与系统性血栓溶解相比,导向导管的干预措施显示出较少出血的趋势.
- 前列腺炎的严重程度是决定治疗方法和预测结果的关键因素.
相关概念视频
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
159
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
159
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
173
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
173